Global drug major Novartis has invested, expanded its research & development (R&D) capabilities in India. The global leader in biosimilars through its subsidiary Sandoz is assessing Indian market dynamics to launch its portfolio. Novartis' global head of drug development, Vas Narasimhan, says that India is still some time away to see investments in basic drug discovery.Also watch Patrick Vallance, President-R&D at GSK and Paul Stoffels of Johnson & Johnson sharing their views on R&D challenges in India.Watch videos for entire conversation.....
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
